(VSOP) A new class of contrast agents with smaller particle size than SPIO or USPIO with advantages for MR angiography, caused through a longer plasma half-life.

See also Ultrasmall Superparamagnetic Iron Oxide and Superparamagnetic Iron Oxide.

Blood pool agents (intravascular contrast agents) remain in the blood for a prolonged time compared with conventional contrast agents, which diffuse quickly into the interstitial space. Magnetic resonance angiography (MRA), cardiovascular imaging, or contrast enhanced MRIs are possible over an hour or more. This advantage over conventional MRI contrast media allows also higher resolution MRA of several territories using respiratory or cardiac gating techniques with a single contrast bolus.
Different types of blood pool contrast agents:
Blood pool MRI contrast agents with their longer intravascular circulation can be designed to be targeted to necrotic myocardium, to assess myocardial viability, or tumor directed to provide better diagnostic information for various tumors. A disadvantage of the use of blood pool agents for MRA is that the separation of arteries and veins is more difficult because they are present in both and the overlapping of those vessels is disturbing. This can be solved by e.g. different MIP segmentation algorithms.

See also Necrosis Avid Contrast Agent, Tumor Specific Agents, Feruglose, Gadofosveset Trisodium (Vasovist), Ultrasmall Superparamagnetic Iron Oxide and Contrast Medium.

A bolus is a rapid infusion of high dose contrast agent. Dynamic and accumulation phase imaging can be performed after bolus injection. Since the transit time of the bolus through the tissue is only a few seconds, high temporal resolution imaging can be required to obtain sequential images during the wash in and wash out of the contrast material and, therefore, resolve the first pass of the tracer.
For the same injected dose of contrast agent the injection rate (and, consequently, the total injected volume) modifies the bolus peak profile. Increasing the injection rate produces a sharpening of the peak (Cmax increase, Tmax decrease, peak length decrease). At a low injection rate, the first pass presents a plateau form. Substantial changes in the gadolinium concentrations during signal acquisition induce artifacts. Furthermore, the haemodynamic parameters (cardiac output, blood pressure) influence the bolus profile. The characteristics of gadolinium agents are favorable in the early bolus phase, whereas the advantages of large complexes (e.g. blood pool agents) and ultrasmall superparamagnetic iron oxide (USPIO) are most evident in the distribution phase.

An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.

See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.

Biphasic oral contrast agents may produce either high or low signal intensities depending on the pulse sequence used, for example low signal intensity on T1 weighted MR images and high signal intensity on T2 weighted images. The combination of different oral contrast agents can generate a macroscopic cancellation of negative and positive magnetic susceptibility, thereby eliminating susceptibility artifacts.
Possible combinations are e.g., ferric ammonium citrate and corn oil, or ferrous sulfate emulsified with baby formula. Paramagnetic agents combined with oil emulsion may be used in MRI as positive abdominal contrast agents. The combination of diamagnetic barium sulfate and superparamagnetic iron oxide (SPIO) in one suspension may be a useful negative contrast agent.

See also Gastrointestinal Paramagnetic Contrast Agents, Gastrointestinal Superparamagnetic Contrast Agents, Gastrointestinal Diamagnetic Contrast Agents, Gastrointestinal Imaging.